← Back to Screener
Intellia Therapeutics, Inc (NTLA)
Price$15.29
Favorite Metrics
Price vs S&P 500 (26W)-42.87%
Price vs S&P 500 (4W)7.88%
Market Capitalization$1.80B
All Metrics
Book Value / Share (Quarterly)$5.77
P/TBV (Annual)2.25x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)9.09%
Cash Flow / Share (Quarterly)$-3.40
Price vs S&P 500 (YTD)65.26%
Net Profit Margin (TTM)-609.85%
EPS (TTM)$-3.83
10-Day Avg Trading Volume2.70M
EPS Excl Extra (TTM)$-3.83
Revenue Growth (5Y)3.14%
EPS (Annual)$-3.81
ROI (Annual)-61.47%
Net Profit Margin (5Y Avg)-910.70%
Cash / Share (Quarterly)$3.87
Revenue Growth QoQ (YoY)78.79%
ROA (Last FY)-49.01%
Revenue Growth TTM (YoY)16.92%
EBITD / Share (TTM)$-3.98
ROE (5Y Avg)-46.19%
Operating Margin (TTM)-651.67%
Cash Flow / Share (Annual)$-3.40
P/B Ratio2.68x
P/B Ratio (Quarterly)1.55x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)24.25x
Net Interest Coverage (TTM)-185.69x
ROA (TTM)-45.20%
EPS Incl Extra (Annual)$-3.81
Current Ratio (Annual)5.08x
Quick Ratio (Quarterly)4.42x
3-Month Avg Trading Volume4.25M
52-Week Price Return110.37%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$11.64
P/S Ratio (Annual)26.55x
Asset Turnover (Annual)0.08x
52-Week High$28.25
Operating Margin (5Y Avg)-936.95%
EPS Excl Extra (Annual)$-3.81
CapEx CAGR (5Y)-20.65%
Tangible BV CAGR (5Y)32.67%
26-Week Price Return-35.98%
Quick Ratio (Annual)4.42x
13-Week Price Return28.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.08x
Enterprise Value$1,641.347
Revenue / Share Growth (5Y)-9.63%
Asset Turnover (TTM)0.07x
Book Value / Share Growth (5Y)-6.23%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-609.85%
Cash / Share (Annual)$3.87
3-Month Return Std Dev79.99%
Net Income / Employee (TTM)$-1
ROE (Last FY)-61.47%
Net Interest Coverage (Annual)-17.53x
EPS Basic Excl Extra (Annual)$-3.81
P/FCF (TTM)31.86x
Receivables Turnover (TTM)7.53x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.83
Receivables Turnover (Annual)7.53x
ROI (TTM)-56.63%
P/S Ratio (TTM)26.55x
Pretax Margin (5Y Avg)-910.70%
Revenue / Share (Annual)$0.62
Tangible BV / Share (Annual)$14.19
Price vs S&P 500 (52W)75.74%
Year-to-Date Return69.19%
5-Day Price Return2.91%
EPS Normalized (Annual)$-3.81
ROA (5Y Avg)-36.29%
Net Profit Margin (Annual)-609.85%
Month-to-Date Return18.64%
Cash Flow / Share (TTM)$-5.25
EBITD / Share (Annual)$-3.98
Operating Margin (Annual)-651.67%
ROI (5Y Avg)-46.19%
EPS Basic Excl Extra (TTM)$-3.83
P/TBV (Quarterly)2.68x
P/B Ratio (Annual)1.55x
Pretax Margin (TTM)-609.85%
Book Value / Share (Annual)$5.77
Price vs S&P 500 (13W)25.76%
Beta2.03x
P/FCF (Annual)60.01x
Revenue / Share (TTM)$0.58
ROE (TTM)-56.63%
52-Week Low$6.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.68
3.60
3.60
3.70
Industry Peers — In Vitro Diagnostics(17)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NTLAIntellia Therapeutics, Inc | 26.55x | 16.92% | — | — | $15.29 |
IDXXIdexx Laboratories Inc | 10.72x | 10.42% | 61.80% | 14.28% | $583.06 |
LNTHLantheus Holdings, Inc | 3.55x | 0.50% | 61.10% | 40.71% | $83.97 |
NNNNAnbio Biotechnology Class A Ordinary Shares | 293.41x | -5.72% | 89.00% | — | $26.98 |
CLDXCelldex Therapeutics, Inc | 1744.87x | -77.98% | 17.65% | — | $34.38 |
NEOGNeogen Corp | 2.39x | -3.91% | 45.20% | — | $9.63 |
QDELQuidelOrtho Corporation Common Stock | 0.32x | -1.89% | 46.67% | — | $12.89 |
MYGNMyriad Genetics Inc | 0.59x | -1.56% | 69.93% | — | $5.14 |
ACHVAchieve Life Sciences, Inc. | 12.70x | -89.25% | — | — | $4.25 |
TKNOAlpha Teknova, Inc. Common Stock | 3.87x | 7.35% | 33.17% | — | $2.91 |
IMDXInsight Molecular Diagnostics Inc. Common Stock | 31.65x | 115.58% | 56.97% | — | $3.99 |
About
Intellia Therapeutics develops CRISPR-based gene therapies to treat genetically defined diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, and sickle cell disease. The company employs both in vivo and ex vivo therapeutic approaches across its pipeline. Strategic partnerships with Regeneron and Novartis provide clinical and commercial validation for its gene-editing platform.